Pembrolizumab plus trastuzumab and chemotherapy for HER2+ metastatic gastric or gastroesophageal junction (G/GEJ) cancer: Initial findings of the global phase 3 KEYNOTE-811 study - Janjigian, Y Y; Kawazoe, A; Yanez, P E (J Clin Orthod, 2021)
(15, suppl):